-+ 0.00%
-+ 0.00%
-+ 0.00%

SLING THERAPEUTICS ANNOUNCES $123 MILLION SERIES C FINANCING TO ADVANCE PHASE 3 DEVELOPMENT OF ITS ORAL SMALL MOLECULE IGF-1R INHIBITOR FOR THYROID EYE DISEASE

Reuters·09/16/2026 11:00:06

Please log in to view news